Efficacy of cyclosporine 0.05% in patients with dry eye syndrome

Phogat, Jitender; Verma, Ranjana; Rathi, Manisha; Sachdeva, Sumit; Pandey, Latika

doi:10.18203/2394-6040.ijcmph20193451

Cited by 2 publications

(4 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similar finding in a study by Henry D. Perry et al 4 where mean age was observed to be 57 years in patients with mild dry eyes and 66 years in patients with moderate dry eyes and 68 years in severe cases. Mean age of the patients was 44.2 years in a study by Jitender Phogat et al 8 and 47 years in a study by Tageldin M. Othman et al, 9 So we can say by this pattern that probability of dry eye disease increases after 40 years of age.…”

Section: Discussionmentioning

confidence: 86%

“…Mean OSDI score in a study by Pinnita Prabhasawat et al 12 was 43.32. In a study by Jitender Phogat et al 8 the score of ocular symptoms before the beginning of the treatment was 2.25±0.41 and this score improved after 4 weeks to 1.36±0.14, to 1.11±0.18 after 8 weeks, and to 0.6±0.44 after 12 weeks with a statistically significant difference (p=0.01).…”

Section: Discussionmentioning

confidence: 92%

“…In accordance similar results were observed in a study by Haitham Y et al 13 BUT test showed early break-up of the tear film before the beginning of the treatment (5.57± 1.36 s), which improved after 1 month of treatment to 8.02 ±0.98 s, 7.28± 0.15 s after 2 months, and 9.9± 0.92 s, with a statistically significant difference after 3 months (P = 0.001). BUT test results in a study by Jitender Phogat et al 8 showed early tear 13 Schirmer's paper test, which showed a wetting of 1.15± 0.58 mm before treatment and improved to 2.2± 0.12 mm after 1 month, 4.82± 0.51 mm after 2 months, and 5.86 ±0.29 mm after 3 months with a statistically significant difference.…”

Section: Discussionmentioning

confidence: 93%

“…Females are at a substantial risk factor for both DED and MGD development. 8,10,11 Because the androgen and oestrogen receptors are both present inside the meibomian glands, this could be related to the effect of hormonal changes on meibomian production.…”

Section: Discussionmentioning

confidence: 99%

See 3 more Smart Citations

A study to assess the efficacy of topical cyclosporine A 0.05% in the management of dry eye with meibomiam gland dysfunction

Reddy¹,

Umam²

2022

IJCEO

View full text Add to dashboard Cite

: Dry eye is a multifactorial disease of the tears and ocular surface that results in symptoms of discomfort, visual disturbance, and tear film instability with potential damage to the ocular surface. It is accompanied by increased osmolarity of the tear film and inflammation of the ocular surface. Meibomian Gland Dysfunction (MGD) is an abnormality of the meibomian gland that blocks the secretion of lipids. Without sufficient lipid production, tears evaporate quickly causing Dry Eye.MGD is associated with multiple pathological mechanisms including inflammation, microbial factors and lipid deficiencies. Topical Cyclosporine A (CsA) 0.05% is a calcineurin inhibitor that reduces inflammation by specifically inhibiting T‑cell activity, which reduces ocular surface inflammation and improves tear film dynamics. This was a prospective observational study done on 100 patients at the Department of Ophthalmology Basaveshwar teaching and general hospital, on patients of dry eyes due to meibomian gland dysfunction. Patients who were diagnosed with dry eyes due to meibomian gland dysfunction were invited to take part in the study. Patients were divided randomly into two groups of 50 patients each. This study, was explained in detail to them. An informed consent was obtained. Patients fulfilling the inclusion criteria were listed.All OSDI scores (symptom intensity, frequency and aggravation) revealed decreasing patterns throughout the observation period in both the groups. In single analysis, the cyclosporine A 0.05% group showed a significant improvement for each score at 3 months (p < 0.01, p = 0.01, p = 0.02, respectively). The mean TBUT after treatment in the group A (cyclosporine A group) increased to 12.36± 3.58(p<0.001) seconds, and in the group B (Control group) the TBUT score increased to 11.01±3.06 seconds. After 3 Months, there was statistically significant improvement in the mean Schirmer’s scores in both the treatment groups, however improvement was significantly greater in Cyclosporine A group. Prior to the treatment in group A (Cyclosporine A) mean Lissamine staining score was 2.73±0.15 and post treatment it reduced to 1.32±0.15 which was statistically significant (P<0.001). In group B (Control group) score before treatment was 2.46±0.15 and after treatment it reduced to 2.39±0.27 (p=0.11), not much difference was seen. : Findings from our study showed that there were significant improvements in the dry eye conditions due to defect in meibomian gland by treatment of topical Cyclosporine A 0.05% and sodium hyaluronate 0.1%.

show abstract

Section: Discussionmentioning

confidence: 86%

Section: Discussionmentioning

confidence: 92%

Section: Discussionmentioning

confidence: 93%

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

A study to assess the efficacy of topical cyclosporine A 0.05% in the management of dry eye with meibomiam gland dysfunction

Reddy¹,

Umam²

2022

IJCEO

View full text Add to dashboard Cite

show abstract

Topical Cyclosporine A 0.05% for the Treatment of Dry Eye Disease

Elzlitni

Bukhatwa

Eldressi

2021

MJSc

View full text Add to dashboard Cite

Dry eye disease (DED) is a common clinical condition that challenges ophthalmologists. Topical Cyclosporine A is an anti-inflammatory therapy being approved by the Food and Drug Administration (FDA) for the therapy for DED. This study aimed to evaluate the efficacy and pa- tient tolerability of topical Cyclosporine A 0.05% for the treatment of DED. A total of 87 patients diagnosed with DED were included in this study. Dry eye symptoms (foreign body sensation, burn- ing, and pain) were scored. As a baseline measurement, the tear break-up time test (TBUT) and the Schirmer’s test were performed for all the patients. Cyclosporine A 0.05% was given topically twice daily to all the patients for four months. They were followed up every month for a period of four months. The clinical signs (Schirmer’s test, the TBUT), and the symptoms scores, were record- ed for each visit. The mean age of the patients was 57.25±9.70 years (Range 32 - 80 years); 25 males (28.7%) and 62 females (71.3%). Out of them, 23 (26.4%) cases had Sjögren’s syndrome, and 12 (13.7%) cases had previous LASIK (laser in-situ keratomileusis). The symptoms score of the cases improved from (4.95±1.73) pretreatment to (0.40±.70) four months after treatment (P <0.001). The Schirmer’s test results improved from (4.10 ±1.089) pretreatment to (10.80±2.40) four months post-treatment (P <0.0001), and the TBUT test results improved from (5.54±1.77 s) pre- treatment to (12.95±3.12 s) four months post-treatment (P <0.0001). Only seven patients (8%) de- veloped ocular side effects in the form of redness, pain, and systemic side effects in the form of headache. In conclusion, Cyclosporine A 0.05% eye drops is an effective treatment for DED, im- proving both signs and symptoms of DED with few ocular side effects.

show abstract

Efficacy of cyclosporine 0.05% in patients with dry eye syndrome

Cited by 2 publications

References 12 publications

A study to assess the efficacy of topical cyclosporine A 0.05% in the management of dry eye with meibomiam gland dysfunction

A study to assess the efficacy of topical cyclosporine A 0.05% in the management of dry eye with meibomiam gland dysfunction

Topical Cyclosporine A 0.05% for the Treatment of Dry Eye Disease

Contact Info

Product

Resources

About